Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 5/20 | 0.32 |
| ▸ | PGR | P06401 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10123635 | 0.86 | GABRA1 (0.37) | ARPGR | |
| SCHEMBL343412 | 0.82 | CA2 (0.37) | KIF11ARPGRALDH1A1KDM4E | |
| SCHEMBL10123575 | 0.76 | MAOA (0.35) | ARALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL22955471 | 0.75 | CDK2 (0.38) | KIF11FNTAFNTBPGGT1BALDH1A1 | |
| SCHEMBL26997353 | 0.73 | KDM4E (0.35) | KIF11FNTAFNTBPGGT1BALDH1A1 | |
| SCHEMBL10123651 | 0.73 | CDC7 (0.33) | ALDH1A1KDM4E | |
| SCHEMBL26997223 | 0.72 | ALDH1A1 (0.33) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL10123632 | 0.71 | ALDH1A1 (0.34) | ARPGRALDH1A1HPGDKDM4E | |
| SCHEMBL344208 | 0.71 | KDM4E (0.43) | ARPGRALDH1A1HPGDALOX15 | |
| SCHEMBL10123594 | 0.71 | CYP2A6 (0.38) | ALDH1A1HPGDTDP1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-8748452-B2 | Indolizine derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| US-8748452-B2 | Indolizine derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, INMT, PON1 | KIF11 4632/4885FNTA 2059/4885FNTB 3668/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KIF11 1969/4885FNTA 608/4885FNTB 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.